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Abstract
Background:  Previous research indicates that many patients with fractures indicative of
underlying osteoporosis are not receiving appropriate diagnostic follow-up and therapy. We
assessed osteoporosis treatment coverage in older home care clients with a diagnosis of
osteoporosis and/or prevalent fracture.
Methods: Subjects included 330 home care clients, aged 65+, participating in a longitudinal study
of medication adherence and health-related outcomes. Data on clients' demographic, health and
functional status and service utilization patterns were collected using the Minimum Data Set for
Home Care (MDS-HC). A medication review included prescribed and over-the-counter
medications taken in the past 7 days. Criteria for indications for osteoporosis therapy included
diagnosis of osteoporosis or a recent fracture. Coverage for treatment was examined for anti-
osteoporotic therapies approved for use in 2000.
Results: Of the 330 home care clients, 78 (24%) had a diagnosis of osteoporosis (n = 47) and/or
had sustained a recent fracture (n = 34). Drug data were available for 77/78 subjects. Among the
subjects with osteoporosis or a recent fracture, 45.5% were receiving treatment for osteoporosis;
14% were receiving only calcium and vitamin D, and an additional 31% were receiving drug therapy
(bisphosphonate or hormone replacement therapy). The remaining 54.5% of subjects were not
receiving any approved osteoporosis therapy.
Conclusions: The high prevalence of undertreatment among a population of older adults with
relatively high access to health care services raises concern regarding the adequacy of diagnosis and
treatment of osteoporosis in the community.
Background
Osteoporosis is defined as ' . . .a skeletal disorder charac-
terized by compromised bone strength predisposing a
person to an increased risk of fracture. Bone strength
reflects the integration of two main features; bone density
and bone quality' [1]. The presence of a vertebral or other
fragility fracture is a strong predictor of risk of future frac-
ture, and is a major indicator of the presence of oste-
oporosis [2-4]. A fragility fracture is defined as a low
trauma fracture (eg. a fall from a standing height or less)
[3]. Many studies indicate that fewer than 30% of patients
with fragility fractures are being treated for osteoporosis.
Rates of treatment appear particularly low following hos-
pital discharge (<10%) [5-7], suggesting that treatment
recommendations are not being made to family physi-
cians. Assessment of treatment rates 6 months to 2 years
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after fracture are somewhat higher (in the 20–38% range)
[8-13]. Kiebzak et al. followed patients for 1–5 years after
hip fracture. At follow-up, they found that 71% of women
were receiving treatment, but the proportion of men
receiving therapy remained relatively low [14]. Four Cana-
dian studies of osteoporosis treatment following fragility
fracture were identified. Two studies examined osteoporo-
sis treatment among hip fracture patients after hospital
discharge, and in both, treatment rates were relatively low
(< 10%) [6,15]. In Ontario, Hajcsar et al. interviewed
patients one year after fragility fracture, and found that the
use of approved pharmaceutical agents such as bisphos-
phonates and hormone replacement therapy (HRT)
remained low (7.4% and 16%, respectively) [13]. Khan et
al. reported considerably higher treatment rates among
patients after wrist fracture, with approximately 38% of
patients receiving either a bisphosphonate or HRT at fol-
low-up [9].
The purpose of this study was to examine osteoporosis
treatment among older home care clients with a diagnosis
of osteoporosis and/or prevalent fracture. As this popula-
tion has relatively frequent contact with health care pro-
viders, we expected that osteoporosis treatment rates
should be higher than previously reported.
Methods
Participants were 330 older home care clients participat-
ing in a longitudinal study of medication adherence and
related health outcomes. Details of the primary study can
be found elsewhere [16]. Briefly, between April and June
of 2000, 585 home care clients residing in two southern
Alberta health regions were identified by random samples
stratified by rural/urban residence. Rural clients repre-
sented those living on a farm, acreage or in a village or
town (with a population less than 10,000) and residing
greater than 35 km from a major urban centre (cities of
Calgary or Lethbridge). Inclusion criteria were: currently
receiving home care services under the jurisdiction of their
respective health region, age 65 or greater and provision
of informed consent from either the subject or a legal
guardian. Of the original random sample of 585, 10 sub-
jects had died and 10 had moved or were unavailable at
the time of study recruitment. Further exclusions included
subjects who were in hospital, transferred to long term or
palliative care, or mentally incompetent without a legal
guardian (n = 40), who required a translator (n = 6) or
who posed a safety concern for the study nurses (n = 7).
Of the remaining 512 subjects, 46 (9.0%) refused to par-
ticipate and 136 (26.6%) were not contacted after the pre-
determined sample size (based on estimation of
differences in adherence rates between rural and urban
subjects) [16] had been achieved.
Data on demographics, health and functional status and
service utilization were collected with a standardized
assessment tool, the Minimum Data Set for Home Care
(MDS-HC) [17,18], and several supplemental questions
regarding medication use, smoking and tobacco use.
Information on therapeutic substances was recorded from
container labels for all substances used in the past 7 days.
Therapeutic substances included prescribed, over-the-
counter and complementary or alternative products. All
drug data were entered into a database using the Anatom-
ical Therapeutic Chemical classification system (ATC
codes). Assessment of medication adherence was based
on self-report data [16]. Four study nurses, trained in the
administration of the MDS-HC and medication assess-
ment, collected data during in-home interviews lasting
approximately 1.5 hours. This study received ethics
approval from the Health Research Ethics Board of the
University of Calgary and the Ethics Review Committee of
the Chinook Health Region.
Fracture prevalence and diagnosis of osteoporosis were
determined from the disease diagnoses section of the
MDS-HC (Section J). The MDS-HC includes specific cate-
gories for charting of: 'hip fracture', 'other fracture', and
'osteoporosis'. Prevalent fractures were defined as those
that had resulted in a hospitalization (in last 90 days),
currently required treatment and/or symptom manage-
ment or were being monitored by a home care profes-
sional. Coverage for treatment was examined for anti-
osteoporotic therapies approved for use in 2000 [19].
These included calcium with vitamin D, and the following
pharmaceutical agents: etidronate, alendronate, hormone
replacement therapy, raloxifene and calcitonin.
Prevalence estimates of treatment for osteoporosis among
subjects with a prevalent fracture and/or diagnosis of oste-
oporosis were reported. Descriptive bivariate comparisons
were also conducted to examine potential variations
between osteoporotic subjects who received treatment
and those who did not. Fisher's exact test was reported for
the bivariate comparisons. Due to the limited number of
subjects with osteoporosis or fracture, multivariable anal-
yses were not feasible.
Results
Demographic and health status variables are summarized
in Table 1. The mean age of the total sample (n = 330) was
82 years (standard deviation = 7.8, range 65–101) and
most clients were female (78.5%) and not married
(70.6%). Almost half (41.8%) had completed at least
high school education and a substantial proportion of
subjects lived in a seniors' lodge (36.7%). A total of 78
subjects (23.6%) had at least one potential indication for
osteoporosis treatment. The demographic characteristics
of these subjects were similar to the sample as a wholeBMC Musculoskeletal Disorders 2005, 6:7 http://www.biomedcentral.com/1471-2474/6/7
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(Table 1), with the exception that this group included a
greater proportion of women (93.6%). Demographic data
were only available for a sub-group of all non-respond-
ents. Analyses of this sub-sample showed no significant
differences between non-respondents and respondents in
relation to age and sex.
The prevalence of osteoporosis diagnoses and fractures are
summarized in Table 2. Forty-seven subjects (14.2%) had
a diagnosis of osteoporosis, three of whom had at least
one prevalent fracture. Prevalence of at least one fracture
without diagnosis of osteoporosis was recorded for 31
(9.4%) subjects; 13 hip fractures (1 with 'other fracture'),
and 18 with 'other' fractures. One client had only unla-
belled medication bottles, thus medication data were
available for 77 of these subjects. Approximately 50% of
subjects with a diagnosis of osteoporosis or prevalent hip
fracture received treatment, compared to only 28% of sub-
jects with 'other' fractures (p = 0.11).
Specific therapeutic interventions for osteoporosis among
subjects with a diagnosis of osteoporosis and/or fracture
are shown in Figure 1. No subjects were using calcitonin
or raloxifene. In total, only 35 subjects (45%) were
receiving at least minimal treatment for osteoporosis (i.e.
at least calcium with vitamin D). Only 30 subjects (39%)
were receiving therapy with an approved prescription
drug (bisphosphonate and/or hormone replacement ther-
apy), with 5 subjects (6%) being treated only with
calcium and vitamin D. Six subjects receiving prescription
drug therapy were also taking calcium and vitamin D (not
shown in Figure). Of the 42 subjects not receiving mini-
mal treatment (i.e. drug therapy and/or calcium with vita-
min D), 3 were taking calcium only, and 10 were taking a
Table 1: Summary of demographic characteristics and health status among older home care clients.
Variable Total Study Population N = 330 % (n) Subjects with diagnosis of osteoporosis 
or fracture N = 78 % (n)
Demographics
Age
Mean (SD) 82 (7.8) 83 (8.3)
(≥  85) 43.3 (143) 42.3 (33)
Female 78.5 (259) 93.6 (73)
Not married 70.6 (233) 79.5 (62)
Education (≥  High School) 41.8 (138) 44.9 (35)
Living arrangements
Seniors' Lodge* 36.7 (121) 34.6 (27)
Health Status
Cognitive impairment
(CPS** score >1) 23.3 (77) 24.4 (19)
# Comorbid conditions (>2) 71.8 (237) 71.8 (237)
* Versus private home
** MDS-HC Cognitive Performance Scale
Table 2: Indications for treatment of osteoporosis among older home care clients.
Diagnoses N = 330 Receiving treatment* N = 77
Indication % (n) % (n)
Diagnosis of osteoporosis** 14.2 (47) 50.0 (23/46†)
Hip fracture‡ 3.9 (13) 53.8 (7/13)
'Other' fracture?? 5.5 (18) 27.8 (5/18)
Total 23.6 (78) 45.5 (35/77)
* Treatments included: calcium with vitamin D and/or drug therapy (bisphosphonate or hormone replacement therapy).
** Three subjects also had at least one fracture.
† Medications unlabelled for one subject.
‡ One subject also had 'other fracture'
?? Type of fracture was available for 10/18 subjects: 3 wrist, 1 humerus, 2 ankle, 2 vertebral, 1 shoulder and 1 rib fracture.BMC Musculoskeletal Disorders 2005, 6:7 http://www.biomedcentral.com/1471-2474/6/7
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multivitamin that may have contained calcium and/or
vitamin D. Bivariate comparisons of potential factors that
may influence receipt of treatment are summarized in
Table 3. A greater proportion of nonadherent subjects
were observed in the group that did not receive treatment
(50% versus 31%). The proportion of subjects with lower
education levels was also relatively higher among the
non-treated group. None of the 5 men among the oste-
oporotic group were receiving treatment.
Discussion
Home care clients are expected to have relatively frequent
contact with health care providers. Among those with a
diagnosis of osteoporosis or prevalent fracture (n = 78),
30% had weekly contact with nursing staff, 42% had at
least one emergency or emergent care visit or hospitaliza-
tion in the past 3 months, and the majority (67%) had a
recent (<6 months) review of their total medication regi-
men. Thus, more opportunity for intervention following
Table 3: Comparison of osteoporotic subjects by treatment status. (n = 77)
Variable No Treatment n = 42 % (n) Treatment n = 35 % (n) Fisher's exact p-value
Age (≥  85) 42.8 (18) 42.8 (15) 1.00
Sex (male) 11.9 (5) 0 0.06
Education
(≥  High School) 38.1 (16) 54.3 (19) 0.18
Residence (seniors' lodge) 40.4 (17) 28.6 (10) 0.34
Cognitively impaired 23.8 (10) 22.8 (8) 0.60
Depression 14.3 (6) 14.3 (5) 0.75
Confined to wheelchair/bed 21.4 (9) 20.0 (7) 1.00
Fall(s)in past 90 days 31.0 (13) 22.9 (8) 0.45
On steroid medication 4.76 (2) 11.4 (4) 0.40
Nonadherent (with any prescribed medication) 50.0 (21) 31.4 (11) 0.11
Osteoporosis therapy among subjects with a diagnosis of osteoporosis and/or fracture Figure 1
Osteoporosis therapy among subjects with a diagnosis of osteoporosis and/or fracture. (HRT = hormone replacement ther-
apy) No treatment (n = 29) Calcium only (n = 3) Multivitamin (n = 10) Bisphosphonate (n = 21) HRT (n = 7) Bisphosphonate + 
HRT (n = 2) Calcium + vitamin D only (n = 5)BMC Musculoskeletal Disorders 2005, 6:7 http://www.biomedcentral.com/1471-2474/6/7
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fracture, and higher rates of treatment would be expected
among this population. Although the proportion of home
care clients receiving treatment was somewhat higher than
reported in most previous studies (45% versus  <39%,
respectively) [5-8], [10-13], the majority of subjects with
a diagnosis of osteoporosis or fracture indicative of oste-
oporosis were still not receiving even minimal therapy
(i.e. calcium and vitamin D). Consistent with previous
reports [14], we also found that men were not receiving
therapy following fracture. In this home care sample,
none of the 5 men with indication for osteoporosis treat-
ment were receiving therapy. Three of these men had frac-
tures at sights other than at the hip, where lower
intervention rates were observed even for women. How-
ever, 2 of these men had a charted diagnosis of osteoporo-
sis and were still not receiving treatment.
Our data also indicate that subjects who fracture at sites
other than the hip may be less likely to receive treatment.
While many of the fractures observed in this study (Table
2) were typical of osteoporotic fractures with respect to
fracture site [2,4], our data are limited in that the MDS-HC
does not include an assessment of the cause of the frac-
ture. If some fractures were the result of trauma, our find-
ings may overestimate the deficit in osteoporosis therapy.
Conversely, the prevalence of osteoporosis may be under-
estimated in our study population, as the diagnosis was
based on self-report information. The prevalence of oste-
oporosis in Canadian women aged 50+ years, based on
BMD, has been estimated at 15% [20]. If diagnosis were
based on BMD alone, a higher prevalence would be
expected in the older population in this study. However,
physicians' diagnoses of osteoporosis may derive from
factors other than BMD, and our findings are consistent
with previous work that suggests that many patients with
osteoporosis are not receiving appropriate therapy.
We also examined several factors potentially associated
with undertreatment. However, the small numbers of sub-
jects with osteoporosis or prevalent fracture limit the
interpretation of our findings. Although some trends are
apparent, such as undertreatment of men and those with
lower education, we cannot comment conclusively on
these observations due to the limited sample size and
cross-sectional nature of the study. Further evaluation of
these factors utilizing a larger sample and appropriate
multivariable analysis may provide further insight regard-
ing the potential impact of specific determinants.
Speculation regarding reasons for the apparent under-
treatment of osteoporosis has focused on physician
oversight. However, several factors may play a role in the
choice to initiate treatment. A recent study indicated that
some physicians have concerns about the proven efficacy
of osteoporosis treatment among older populations and
may be exercising judgment with respect to minimizing
polypharmacy in this population [21]. Further, physicians
are not the only factor involved in decisions to initiate,
and/or continue with therapy. In a study conducted by
McKercher et al., physicians reported that the choice to
initiate osteoporosis treatment was also dependent upon
acceptance of the therapy by patients and/or family mem-
bers [21]. Interviews with patients following fragility frac-
ture also indicate that some patients choose not to use
osteoporosis therapy [8,13] (e.g. concerns about side
effects). The higher rate of nonadherence with medica-
tions among those not receiving therapy in this study, also
suggests that lack of therapy may be due to patient
choices. However, the assessment of adherence by self-
report, as used in this study, only provided a measure of
adherence with overall drug regimens, not specific medi-
cations. Collection of more detailed information on
adherence with specific osteoporosis therapies in future
studies may clarify this association.
Despite limitations, our findings highlight the growing
concern that many patients with osteoporosis are not
receiving appropriate therapeutic interventions. The lower
treatment rate among subjects with fractures at sites other
than the hip suggests that physicians may not be recogniz-
ing the probability of underlying osteoporosis. While the
diagnosis of osteoporosis by BMD measurement has been
widely publicized, recent clinical practice guidelines have
emphasized the importance of a history of fragility frac-
ture in the identification of patients with osteoporosis [3].
Our findings suggest that improving recognition of oste-
oporosis among older persons presenting with fractures
may be an important educational objective for practicing
physicians.
Conclusions
Four previous studies conducted in Canada have exam-
ined osteoporosis diagnosis and treatment interventions
following fracture. Our data confirm low treatment rates
among patients with fracture, and also indicate that even
patients with a documented diagnosis may not be receiv-
ing therapy. The reasons for lack of treatment of oste-
oporosis are not yet clear. The reports of patient and
physician concerns regarding side effects and
polypharmacy warrant further investigation, and suggest
that nonpharmacologic interventions may be more
acceptable in certain patient populations. Considering the
complexity of issues involved in decisions to initiate and
continue with treatment, future studies focusing more on
evaluation of physician and patient awareness of oste-
oporosis and factors influencing treatment decisions are
needed.
Evaluation of other patient-related factors, such as adher-
ence and persistence with osteoporosis therapy, and theirBMC Musculoskeletal Disorders 2005, 6:7 http://www.biomedcentral.com/1471-2474/6/7
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impact on health outcomes (e.g. fracture), are also rele-
vant. Such studies may provide insight regarding specific
interventions needed to reduce risk of morbidity and mor-
tality associated with osteoporosis.
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